Mark de Rosch
Keine laufenden Positionen mehr
Vermögen: 34 344 $ am 31.03.2024
Profil
Mark de Rosch worked as a Senior Director-Global Regulatory Strategy at Vertex Pharmaceuticals, Inc. from 2003 to 2012, as a Director-Regulatory Affairs at Berlex Laboratories, Inc. from 2001 to 2003, as a Vice President-Regulatory Affairs at Inspiration Biopharmaceuticals, Inc. from 2012 to 2013, as a Senior VP-Regulatory Affairs & Quality Assurance at Akebia Therapeutics, Inc. from 2014 to 2018, as a Chief Regulatory Officer at Epizyme, Inc. from 2019 to 2021, and as a Senior VP-Regulatory Affairs & Quality Assurance at Nightstar Therapeutics Ltd.
in 2018-2019.
He also worked as a Research Chemist at Mallinckrodt Medical, Inc. from 1992 to 1994 and at Diatide, Inc. from 2000 to 2001.
Dr. de Rosch holds a graduate and doctorate degree from the University of California San Diego and an undergraduate degree from the University of Wisconsin Parkside.
He also worked as a VP-Regulatory Drugs & US Operations at Voisin Consulting, Inc.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
AURA BIOSCIENCES INC
0,01% | 31.03.2023 | 4 375 ( 0,01% ) | 34 344 $ | 31.03.2024 |
Ehemalige bekannte Positionen von Mark de Rosch
| Unternehmen | Position | Ende |
|---|---|---|
| AURA BIOSCIENCES, INC. | Chief Operating Officer | 30.05.2023 |
| EPIZYME, INC. | General Counsel | 01.03.2021 |
| NIGHTSTAR THERAPEUTICS PLC | General Counsel | 01.09.2019 |
| AKEBIA THERAPEUTICS, INC. | General Counsel | 01.02.2018 |
Inspiration Biopharmaceuticals, Inc.
 Inspiration Biopharmaceuticals, Inc. Medical SpecialtiesHealth Technology Inspiration Biopharmaceuticals, Inc. produces intravenous recombinant therapies and develops non-invasive applications. It offers its products for the hemophilia community. The company was founded by Scott Donnelly Martin and John Read Taylor, Jr. on April 28, 2006 and is headquartered in Boston, MA. | General Counsel | 01.05.2013 |
Ausbildung von Mark de Rosch
| University of California San Diego | Doctorate Degree |
| University of Wisconsin Parkside | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
| AURA BIOSCIENCES, INC. | Health Technology |
| AKEBIA THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 7 |
|---|---|
Inspiration Biopharmaceuticals, Inc.
Inspiration Biopharmaceuticals, Inc. Medical SpecialtiesHealth Technology Inspiration Biopharmaceuticals, Inc. produces intravenous recombinant therapies and develops non-invasive applications. It offers its products for the hemophilia community. The company was founded by Scott Donnelly Martin and John Read Taylor, Jr. on April 28, 2006 and is headquartered in Boston, MA. | Health Technology |
Mallinckrodt Medical, Inc.
 Mallinckrodt Medical, Inc. Medical SpecialtiesHealth Technology Mallinckrodt Medical, Inc. manufactures and markets healthcare products. Its products include contrast media & delivery systems, radiology imaging products, radiopharmaceuticals and urology imaging systems. The company is headquartered in Pointe-Claire, Canada. | Health Technology |
Diatide, Inc.
 Diatide, Inc. Pharmaceuticals: GenericHealth Technology Diatide, Inc. is a company based in Londonderry, NH. Diatide, Inc. was founded by André L. Lamotte. | Health Technology |
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
| Berlex Laboratories, Inc. | |
Voisin Consulting, Inc.
 Voisin Consulting, Inc. Miscellaneous Commercial ServicesCommercial Services Voisin Consulting, Inc. provides product development consulting services. It guides biotechnology, pharmaceutical and medical technology manufacturers throughout product development and commercialization. The company was founded by Emanuelle M. Viosin in 1997 and is headquartered in Cambridge, MA. | Commercial Services |
Nightstar Therapeutics Ltd.
 Nightstar Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Nightstar Therapeutics Ltd. is a clinical-stage gene therapy. It engages in the development and commercialization of novel one-time treatments for patients suffering from rare inherited retinal diseases. The company was founded by Robert MacLaren, Miguel Seabra and Matthew During in 2014 and is headquartered in London, the United Kingdom. | Health Technology |
